-
It is not only vaccines that can reduce the risk of new crown pneumonia sequelae
Time of Update: 2023-02-03
STOIC research published in The Lancet Respiratory Medicine suggests that short-term inhaled corticosteroids, budesonide, may be an effective treatment for COVID-19 in early adulthood [3].
STOIC research published in The Lancet Respiratory Medicine suggests that short-term inhaled corticosteroids, budesonide, may be an effective treatment for COVID-19 in early adulthood [3].
-
The National Health Insurance Administration responded that Pfizer's new crown treatment drugs were not included in medical insurance
Time of Update: 2023-02-01
In response to Pfizer's failure to enter the medical insurance catalog through medical insurance negotiations, Huang Xinyu, deputy director of the Department of Pharmaceutical Service Management of the National Medical Insurance Administration, said in Beijing on the 11th that although Paxlovid failed to negotiate successfully this time, according to the current new crown drug reimbursement policy, Paxlovid can still be temporarily reimbursed until March 31, 2023.
-
The four seas will be shocked, and watch the young talents in the field of breast cancer talk and laugh
Time of Update: 2022-11-15
*For medical professionals only for reading and reference, Shanghai famous scholars gather, collide with the spark of wisdom, and play the academic strong voice of the Four Seas Club. Embrace all rive
-
Science Translational Medicine: Parkinson's disease surveillance has made a major breakthrough! Chinese scientists have invented an AI model that can sense and track PD patients through the wall
Time of Update: 2022-11-05
Screenshot of the front page of the paperThey used wireless sensors to collect signals reflected from PD patients and build predictive models using deep learning to assess the severity of PD, disease progression, and the effectiveness of drug therapy (Figure 1).
-
Insoluble particles inspection
Time of Update: 2022-06-28
(5) Insoluble particles inspection1. Brief description(1) Insoluble particles are used to check the insoluble particles in intravenous injections (solution injection, sterile powder for injection, co
-
FDA grants priority review to futibatinib, FGFR inhibitor tripartite situation may be broken
Time of Update: 2022-04-27
In April 2021, futibatinib was granted Breakthrough Drug Designation by the FDA for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring FGFR2 gene rearrangements .
-
The first domestic dictionary-type anti-Paris reading book "Anti-Paris Dictionary" was released 25 experts in the field of Parkinson's disease participated in the editing and review
Time of Update: 2022-04-23
Professor Chen Shengdi from the Department of Neurology, Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, the leader of the society, pointed out that there are about 3 million Parkinson's disease patients in China, and the incidence rate of middle-aged and elderly people over 65 years old is 1.
-
The National Cancer Center's latest release: More than half of patients with these 5 common cancers are diagnosed at an advanced stage
Time of Update: 2022-02-25
" , promoting the development of early screening and testing programs in the future, and even improving medical access are important!The current multicenter, hospital-based observational study included 23 hospitals in 12 provincial-level regions in China, and focused on five common cancers in China: lung, stomach, esophagus, colorectal, and breast cancer .
-
[Coal Chemical Industry] Experts advocate the industry to strengthen the whole process management of hazardous waste
Time of Update: 2022-01-16
In response to the difficulty of selecting hazardous waste technology for chemical companies, Fang Jianzhong, deputy general manager and technical director of the hazardous waste medical waste business department of Tus Environmental Solid Recycling Center, suggested that first, fully understand and master the physical and chemical characteristics of the materials to be disposed of, and consider the technology and equipment.
-
Nuggets overweight/obesity drug market GLP-1 receptor agonists do their part
Time of Update: 2022-01-02
At present, a variety of GLP-1 receptor agonists in China have been developed for overweight/obesity.
The drug is a long-acting molecule that is injected once a week and has been shown to effectively control blood sugar and reduce the weight of subjects in early clinical trials .
-
NEJM: Daprodustat treats anemia in chronic kidney disease undergoing dialysis
Time of Update: 2021-12-26
The primary endpoint of the study was the average change in hemoglobin levels from baseline examination to weeks 28-52 and the first major adverse cardiovascular event (combination of death from any cause, non-fatal myocardial infarction, or non-fatal stroke) .
-
European Radiology: Prognostic value of MRI parapharyngeal subspace involvement in nasopharyngeal carcinoma
Time of Update: 2021-12-04
Previous studies have explored the impact of PPSI sub-categories on the prognosis of nasopharyngeal carcinoma, based on the division of the parapharyngeal space into two intervals, such as the prepharyngeal space and the posterior pharyngeal space , the carotid artery sheath (CS) and the area outside the CS , Parapharyngeal part and parapharyngeal part .
-
The first! Takeda's antiviral therapy Livtencity receives FDA approval
Time of Update: 2021-12-01
S. FDA announced that it has approved Takeda’s development of the antiviral therapy Livtencity (maribavir) for the treatment of refractory adults or children over 12 years of age after hematopoietic stem cell transplantation (HSCT) or solid organ transplantation (SOT).
-
Hengrui Pharmaceuticals PD-L1 in the treatment of extensive-stage small cell lung cancer phase III clinical study reached the primary endpoint
Time of Update: 2021-11-15
Recently, Hengrui Medicine's new class 1 drug PD-L1 monoclonal antibody SHR-1316 (Adbelizumab injection) combined with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer is a randomized, double-blind, placebo-controlled, multi-center phase III The main research endpoint of the clinical study (SHR-1316-III-301) reached the pre-specified superiority standard .
-
Front Oncol: Efficacy of induction chemotherapy combined with intensity-modulated radiotherapy (IMRT) in the treatment of patients with simultaneous metastatic nasopharyngeal carcinoma
Time of Update: 2021-10-20
Recently, Frontiers in Oncology published the results of a study completed by the Shanghai Fudan University team, mainly to evaluate the efficacy and impact of induction chemotherapy + intensity-modulated radiotherapy (IMRT) in patients with nasopharyngeal carcinoma initially diagnosed with distant metastasis Prognostic factors .
